Cypre Status
The company raised $150,000 of convertible debt funding from undisclosed investors on August 24, 2018. Earlier, the company raised an undisclosed amount of venture funding from Hemi Ventures on January 1, 2017.
Developer of a tumor microenvironment system intended to be used for the transformative 3D cellular research and clinical testing of cancer patients. The company's tumor microenvironment system consists of extracellular matrix remodeling, immune infiltration and other processes that influence tumor progression, enabling medical institutions with better and advanced drugs, opening the door for a new generation of therapeutics and patient success.
Year Founded
2016
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cypre News and Updates
HS Roundup: South's Daugherty, Cape's Moore, Neumann's Bergstrom all join 1,000-point club - News
News-Press | January 6, 2021
HTSI gift guide: Lucia van der Post’s wishlist
Financial Times | November 13, 2020
Sierra school zone extended for Ecole Les Cypres
Medicine Hat News | August 29, 2020
BP : Second Quarter 2020 Financial Results and Strategy Presentation
marketscreener.com | August 4, 2020
Cypre's Verticals
Cypre Primary Industry Sector / Group / Code
Cypre's Trends
Cypre Metrics
Majestic Referring Domains
Headquarters
-
HQ Address Line 1953 Indiana Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cypre's Keywords
mood_badFeed is empty.
Add a review